Original news and analysis on international IP policy
With discussions in full swing at the World Intellectual Property Organization on how to protect genetic resources in intellectual property rights, and in particular whether the disclosure of the source of genetic resources should be mandatory in patent applications, the United States has tabled a document hypothetically applying the mandatory disclosure legislation of Switzerland to a US patent.
In the light of the UN High-Level Panel on Access to Medicines, this series of sponsored articles challenges experts to give their views on the policies that best support the development of solutions to societies’ greatest challenges and how enabling policy environments, including IP systems, influence the development and flow of new technologies and services in different sectors, fields of technology, and jurisdictions. The views expressed in the articles are those of the authors. Below is an interview with Dr. Kristina M. Lybecker, Associate Professor of Economics at Colorado College in Colorado Springs (US).
As standardisation increasingly takes place at the global level, Europe needs a speedier, more streamlined way to set the technical specifications that define requirements for products, production processes, services and test methods, the European Commission said today. As part of its single market strategy, the EC announced plans for a joint initiative on standardisation (JIS), guidance to boost the development of European standards, and an annual reporting system among EU institutions on how the standardisation policy is working and contributing to competitiveness, jobs and growth.
According to a new study by experts at the World Health Organization, prices of hepatitis C treatments are unaffordable globally and put a major strain on national health systems. Hepatitis C can cause liver cirrhosis and cancer, and with an estimated 80 million people affected in the world, if untreated, the sickness could lead to 700,000 deaths per year worldwide, the study said, suggesting that governments and industry stakeholders should develop and implement fair pricing frameworks.
World Health Organization members sent a clear signal at the annual Assembly last week when they committed to step up efforts to find ways to fund research into diseases that results in affordable products, according to the top WHO official working on these issues.
Dans le sillage du Groupe de Haut Niveau des Nations Unies sur l’accès aux médicaments (UN High-Level Panel on Access to Medicines) cette série d’articles sponsorisés convie des experts à donner leur point de vue sur les politiques les mieux à même de favoriser l’élaboration de solutions aux plus importants enjeux sociétaux, ainsi que sur la manière dont un cadre réglementaire favorable –y compris les systèmes de protection de la propriété intellectuelle – influence le développement et la diffusion de nouvelles technologies et de nouveaux services au sein de différents secteurs, domaines technologiques et juridictions. Les opinions exprimées dans ces articles n’engagent que leurs auteurs.
Tomando como referencia el trabajo del Grupo de Alto Nivel de las Naciones Unidas sobre el Acceso a los Medicamentos (UN High-Level Panel on Access to Medicines), esta serie de artículos patrocinados invita a expertos en la materia a expresar sus puntos de vista sobre las políticas que respaldan con mayor eficacia la formulación de soluciones que respondan a los principales desafíos de las sociedades, y sobre cómo los entornos propicios para la implantación de políticas, incluidas las relativas a los sistemas de propiedad intelectual, influyen en el desarrollo y el caudal de nuevas tecnologías y servicios en diferentes sectores, campos tecnológicos y territorios. Las opiniones expresadas en los artículos son las del autor.
Today, the annual World Health Assembly is poised to approve a new plan on research and development into medical products that are affordable to all. NGOs, industry and other observers welcomed the outcome.
A closed-door drafting group this evening arrived seemingly easily at agreement on a resolution on broadening work on new ways to fund research and development into medical products, according to participants. The agreement includes the creation of a new expert committee on health R&D, and asks for a WHO proposal on a pooled fund, they said. [Update: draft text now available]
Two years after Ebola, the World Health Organization continues to push forward with a thorough overhaul of how it responds to health emergencies. These include Public Health Emergencies of International Concern (PHEICs), such as the Ebola and Zika outbreaks, as well as natural diseases, conflicts, refugee crises, and the like.